Zobrazeno 1 - 10
of 47
pro vyhledávání: '"treatment-free remission (TFR)"'
Autor:
Karg, Elena, Baldow, Christoph, Zerjatke, Thomas, Clark, Richard E., Roeder, Ingo, Fassoni, Artur C., Glauche, Ingmar
Introduction: Discontinuation of tyrosine kinase inhibitor (TKI) treatment is emerging as the main therapy goal for Chronic Myeloid Leukemia (CML) patients. The DESTINY trial showed that TKI dose reduction prior to cessation can lead to an increased
Externí odkaz:
https://tud.qucosa.de/id/qucosa%3A91771
https://tud.qucosa.de/api/qucosa%3A91771/attachment/ATT-0/
https://tud.qucosa.de/api/qucosa%3A91771/attachment/ATT-0/
Autor:
Paulina Kwaśnik, Joanna Zaleska, Dorota Link-Lenczowska, Magdalena Zawada, Hubert Wysogląd, Bogdan Ochrem, Grażyna Bober, Ewa Wasilewska, Iwona Hus, Monika Szarejko, Witold Prejzner, Olga Grzybowska-Izydorczyk, Agnieszka Klonowska-Szymczyk, Ewa Mędraś, Michał Kiełbus, Tomasz Sacha, Krzysztof Giannopoulos
Publikováno v:
Cells, Vol 13, Iss 8, p 723 (2024)
Treatment-free remission (TFR) is achieved in approximately half of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors. The mechanisms responsible for TFR maintenance remain elusive. This study aimed to identify immune ma
Externí odkaz:
https://doaj.org/article/c7e72887b430405ca12d1be455f84335
Autor:
Simona Bernardi, Michele Malagola, Mirko Farina, Nicola Polverelli, Federica Re, Domenico Russo
Publikováno v:
Hemato, Vol 4, Iss 1, Pp 1-11 (2022)
The effective and sensitive monitoring of Minimal Residual Disease or Measurable Residual Disease (MRD) is a very important aspect in the management of patients affected by hematologic malignancies. The recent availability of new technologies has ope
Externí odkaz:
https://doaj.org/article/48df3dd0fbf046e9889bd77c5cdc48fa
Autor:
Elena Karg, Christoph Baldow, Thomas Zerjatke, Richard E. Clark, Ingo Roeder, Artur C. Fassoni, Ingmar Glauche
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionDiscontinuation of tyrosine kinase inhibitor (TKI) treatment is emerging as the main therapy goal for Chronic Myeloid Leukemia (CML) patients. The DESTINY trial showed that TKI dose reduction prior to cessation can lead to an increased nu
Externí odkaz:
https://doaj.org/article/02f53142ebb54357bbd60724872348d6
Autor:
Alessandra Iurlo, Daniele Cattaneo, Silvia Artuso, Dario Consonni, Elisabetta Abruzzese, Gianni Binotto, Monica Bocchia, Massimiliano Bonifacio, Fausto Castagnetti, Sara Galimberti, Antonella Gozzini, Miriam Iezza, Roberto Latagliata, Luigiana Luciano, Alessandro Maggi, Maria Cristina Miggiano, Patrizia Pregno, Giovanna Rege-Cambrin, Sabina Russo, Anna Rita Scortechini, Agostino Tafuri, Mario Tiribelli, Carmen Fava, Gianantonio Rosti, Robin Foa, Massimo Breccia, Giuseppe Saglio
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Treatment-free remission (TFR) has become a primary therapeutic goal in CML and is also considered feasible by international guidelines. TKIs dose reduction is often used in real-life practice to reduce adverse events, although its impact on TFR is s
Externí odkaz:
https://doaj.org/article/65c0695e402745059fa9fbd7d9d31204
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Simona Bernardi, Michele Malagola, Camilla Zanaglio, Nicola Polverelli, Elif Dereli Eke, Mariella D’Adda, Mirko Farina, Cristina Bucelli, Luigi Scaffidi, Eleonora Toffoletti, Clara Deambrogi, Fabio Stagno, Micaela Bergamaschi, Luca Franceschini, Elisabetta Abruzzese, Maria Domenica Divona, Marco Gobbi, Francesco Di Raimondo, Gianluca Gaidano, Mario Tiribelli, Massimiliano Bonifacio, Chiara Cattaneo, Alessandra Iurlo, Domenico Russo
Publikováno v:
Cancer Medicine, Vol 8, Iss 5, Pp 2041-2055 (2019)
Abstract Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal in the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level by
Externí odkaz:
https://doaj.org/article/e6d3474f9f274cd68adcb4e933b79eb1
Autor:
Mario Tiribelli, Chiara Cattaneo, Massimiliano Bonifacio, Fabio Stagno, Cristina Bucelli, Luigi Scaffidi, Gianluca Gaidano, Mariella D'Adda, Mirko Farina, Domenico Russo, Eleonora Toffoletti, Elif Dereli Eke, Clara Deambrogi, Simona Bernardi, Francesco Di Raimondo, Michele Malagola, Marco Gobbi, Alessandra Iurlo, Luca Franceschini, Maria Domenica Divona, Nicola Polverelli, Camilla Zanaglio, Micaela Bergamaschi, Elisabetta Abruzzese
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 5, Pp 2041-2055 (2019)
Cancer Medicine, Vol 8, Iss 5, Pp 2041-2055 (2019)
Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal in the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level by real‐t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1094e370f7f142d005fac333aed01e8d
https://doi.org/10.1002/cam4.2087
https://doi.org/10.1002/cam4.2087
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.